JonesTrading Issues Positive Forecast for Definium Therapeutics (NASDAQ:DFTX) Stock Price

Definium Therapeutics (NASDAQ:DFTX) had its target price upped by JonesTrading from $61.00 to $74.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. JonesTrading’s price target would suggest a potential upside of 72.90% from the company’s current price.

Other equities analysts have also recently issued research reports about the company. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Definium Therapeutics in a report on Monday. Robert W. Baird upped their target price on Definium Therapeutics from $37.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday. Citigroup reiterated a “buy” rating on shares of Definium Therapeutics in a research note on Monday. Piper Sandler restated an “overweight” rating and issued a $48.00 price objective (down from $49.00) on shares of Definium Therapeutics in a research note on Friday, May 8th. Finally, Leerink Partners set a $52.00 price objective on shares of Definium Therapeutics and gave the stock an “outperform” rating in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $47.08.

Definium Therapeutics Stock Performance

NASDAQ:DFTX traded up $6.62 during trading hours on Wednesday, hitting $42.80. 10,654,170 shares of the company traded hands, compared to its average volume of 2,139,879. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. Definium Therapeutics has a twelve month low of $6.40 and a twelve month high of $44.54. The firm has a 50-day moving average of $23.28 and a 200 day moving average of $18.75. The stock has a market capitalization of $4.27 billion, a price-to-earnings ratio of -17.19 and a beta of 2.37.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.23). On average, analysts forecast that Definium Therapeutics will post -2.3 EPS for the current year.

Institutional Trading of Definium Therapeutics

Hedge funds have recently modified their holdings of the company. Boxer Capital Management LLC acquired a new stake in shares of Definium Therapeutics during the third quarter worth $1,928,000. Royce & Associates LP bought a new stake in shares of Definium Therapeutics in the 3rd quarter valued at about $955,000. Rosalind Advisors Inc. raised its position in shares of Definium Therapeutics by 78.6% in the 3rd quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock valued at $8,842,000 after acquiring an additional 330,000 shares during the period. Fox Run Management L.L.C. bought a new position in Definium Therapeutics during the 3rd quarter worth approximately $609,000. Finally, Russell Investments Group Ltd. boosted its stake in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares during the last quarter. Institutional investors and hedge funds own 27.91% of the company’s stock.

Key Headlines Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium’s Phase 3 Emerge study for DT120 in major depressive disorder posted positive topline results, meeting the primary endpoint and all key secondary endpoints, boosting investor confidence in the drug’s efficacy. Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
• Positive Sentiment: Analysts at Needham and Robert W. Baird raised price targets on DFTX and reiterated bullish ratings, reflecting improved expectations after the trial win. Analyst updates on Definium Therapeutics
• Positive Sentiment: Lifesci Capital slightly improved its earnings outlook for fiscal 2026 and Q4 2026, suggesting modestly better financial expectations following the recent developments. MarketBeat DFTX analyst and stock data
• Neutral Sentiment: Definium also priced a $700 million upsized public offering at $34.00 per share after initially proposing a $500 million raise, adding balance-sheet strength but likely creating some near-term dilution concerns. Definium Therapeutics Announces Pricing of $700 Million Upsized Public Offering

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.